[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,44,76,102,127,152,184,206,226,258,280,303,325,347,372,400,426,456,480,510,556],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100412057","phase-2-merck-iit-rrp-pembro-and-lenvatinib-100412057",false,"NCT04645602","Merck IIT: RRP Pembro and Lenvatinib","A Pilot Study of Lenvatinib in Combination With Pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis Patients","Inclusion Criteria:\n\n\\- Participants must have histologically or cytologically confirmed respiratory papillomas with radiologic evidence of lung involvement. Subjects can have measurable or non-measurable\\* pulmonary disease based on RECIST 1.1. Non-measurable disease based on RECIST 1.1 is defined as lesions with a short axis less than 10 mm\n\n* For those patients with non-measurable pulmonary disease, participants must have disease at other sites such as the larynx and trachea and must have undergone \\> 3 surgical procedures over a 12-month period.\n* Be required to provide tissue from a newly obtained biopsy of a lesion or an archived specimen. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to the first dose of study drug. Subjects for whom newly obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the PI.\n* Have confirmed human papillomavirus-associated lesions based on in-situ hybridization testing and\u002For polymerase chain reaction which may be performed on a newly obtained biopsy or archived sample.\n* Age ≥18 years.\n* ECOG performance status of 0 to 1.\n* Participants must have adequate organ and marrow function as defined below:\n\n  \\---- Absolute neutrophil count (ANC) ≥1500\u002FμL\n\n  \\---- Platelets ≥100 000\u002FμL\n\n  \\---- Hemoglobin ≥9.0 g\u002FdL or ≥5.6 mmol\u002FL (a)\n  * Creatinine OR Measured or calculated (b) creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × institutional ULN OR ≥30 mL\u002Fmin for participant with creatinine levels \\>1.5 × institutional ULN\n  * Total bilirubin ≤1.5 × institutional ULN OR direct bilirubin ≤ institutional ULN for participants with total bilirubin levels greater than or equal to 1.5× institutional ULN\n  * AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × institutional ULN for participants with liver metastases)\n  * TSH Institutional normal limit\n  * Free T4 Institutional normal limit\n  * Amylase less than or equal to 1.5 x institutional ULN\n  * Lipase less than or equal to 1.5 x institutional ULN\n  * International normalized ratio (INR) OR prothrombin time (PT)\n  * Activated partial thromboplastin time (aPTT)\n\n    * 1.5 × institutional ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n  * ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.\n\n    1. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC)transfusion within last 2 weeks.\n    2. Creatinine clearance (CrCl) should be calculated per institutional standard. -- Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies.\n* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n* Adequately controlled blood pressure with or without antihypertensive medications defined as systolic BP ≤ 140 mmHg and diastolic BP ≤ 90 mmHg at screening with no change in antihypertensive medications within 1 week prior to screening.\n* Female subject of childbearing potential must have a negative serum pregnancy test within 28 days of the first dose of study drug\\*. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n  \\*Please refer to the study calendar for requirements regarding a pregnancy test 24 hours prior to receiving any dose of study medication upon subject enrollment into the study.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n  * Is not a WOCBP as defined below. OR\n  * Is a WOCBP and must be willing to use 2 methods of birth control, or abstain from heterosexual activity during the intervention period and for at least 120 days after the last dose of pembrolizumab or 30 days post lenvatinib, whichever occurs last.\n\nWomen of childbearing potential are those who have not been surgically sterilized or have not been free from menses for greater than 1 year. The methods of surgical sterilization include having had a hysterectomy (removal of the uterus), bilateral oophorectomy (removal of both ovaries), tubal ligation (having your tubes tied), and transvaginal occlusion (blocking the tubes with a coil). The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention - A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention.\n\n* If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months (or 120 days) after completion of pembrolizumab\n* Male participants are eligible to participate if they agree to the following during the intervention period and for at least 7 days after the last dose of Lenvatinib:\n\n  * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.\n\nOR\n\n• Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) as detailed below:\n\n* Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.\n* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed\n\n  * Ability to complete Patient Medication and Blood Pressure diaries by themselves or with assistance.\n  * Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study enrollment.\n\nNote: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible.\n\nNote: If participant received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment. Withhold lenvatinib for at least 7 days prior to elective major surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. Endoscopic debridement of RRP lesions is NOT considered a major surgery.\n\n* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n* Has had major surgery within 3 weeks prior to first dose of study interventions. Note: Adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility.\n* Has received a live vaccine within 30 days prior to the first dose of study drug.\n\nExamples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n\n* Is currently participating in or has participated in a study of an investigational agent within 4 weeks prior to the first dose of study treatment. NOTE: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. NOTE: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, well-differentiated thyroid cancer, follicular lymphoma, carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) invasive cancer derived from RRP, or other indolent malignancy not requiring active treatment are not excluded.\n* History of allergic reactions (greater than or equal to Grade 3) attributed to compounds of similar chemical or biologic composition to pembrolizumab or lenvatinib and\u002For any of its excipients.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection. NOTE: No testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.\n* Has a known history of active TB (Bacillus Tuberculosis).\n* Has urine protein greater than or equal to 1 g\u002F24 hours. Note: Participants with proteinuria \\> 2+ (greater than or equal to100 mg\u002FdL) on urine dipstick testing (urinalysis) will undergo 24-hour urine collection for quantitative assessment of proteinuria.\n\nNote: Urine dipstick is the preferred method for testing urinary protein, however, urinalysis may be used if the use of urine dipsticks is not feasible.\n\n* Electrolyte abnormalities that have not been corrected.\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia associated with hemodynamic instability and requiring medical treatment at screening. Note: Medically controlled arrhythmia would be permitted.\n* Has a LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO).\n* Prolongation of QTcF interval to \\>480 msec, as calculated by either the Bazett or Fridericia formula, as per institutional standard.\n* Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage. The degree of tumor invasion\u002Finfiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage\u002Fnecrosis following lenvatinib therapy.\n* Has a known history of colitis.\n* Has clinically significant gastrointestinal malabsorption syndrome or any other condition that might affect the absorption of lenvatinib.\n* Has preexisting greater than or equal to Grade 3 gastrointestinal or non-gastrointestinal fistula\n* Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.\n* Has a known history of posterior reversible encephalopathy syndrome (PRES).\n* Participants with history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab and\u002For lenvatinib, and breastfeeding should be discontinued.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP).\n\nThe names of the study drugs involved in this study are:\n\n* Pembrolizumab\n* Lenvatinib",[26,27,28],"Human Papilloma Virus","Recurrent Respiratory Papillomatosis","Pulmonary Disease",[26,27,30],"Pulmonary Involvement","RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2025-07-18",{"date":39,"type":20},"2027-12",{"name":41,"class":42},"Yale University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":4,"leadSponsor":73,"locationsCount":43},"100063668","study-of-lung-proteins-in-patients-with-pneumonia-100063668","NCT00077909","Study of Lung Proteins in Patients With Pneumonia","Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates","* INCLUSION CRITERIA:\n* All eligible patients undergoing diagnostic bronchoscopy who provide consent for proteomic analysis of BAL fluid supernatant and chart review of patient characteristics will be included in this study.\n* A parent\u002Fguardian may provide consent for a child age 17 or under and a Legally Authorized Representative (LAR) may provide consent for adults unable to consent.\n\nEXCLUSION CRITERIA:\n\nPatients undergoing bronchoscopy but not wanting to participate with either the chart review or the proteomic analysis of BAL fluid supernatant will be excluded.","3 Years","99 Years",{"count":54,"type":20},750,"OBSERVATIONAL","This study will examine the different types of proteins present in the lungs of patients with pneumonia to explore the causes of different types of the disease. Pneumonia is a condition that causes lung inflammation AND is often caused by an infection. It is usually diagnosed by lung x-rays and listening to the chest with a stethoscope. This method can diagnose pneumonia, but it does not provide information on the cause of the inflammation - information that might be helpful in guiding treatment. This study will measure proteins in the lungs of patients to see if certain proteins are associated with specific forms of pneumonia, and can thus serve as biomarkers for disease.\n\nPatients undergoing diagnostic bronchoscopy at the NIH Clinical Center may participate in this study. Patients will undergo bronchoscopy and bronchoalveolar lavage as scheduled for their medical care. For this procedure, the patient's mouth and throat are numbed with lidocaine; a sedative may be given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways carefully. Saline (salt water) is then injected through the bronchoscope into the air passage, acting as a rinse. A sample of fluid is then withdrawn for microscopic examination. Researchers in the current study will use some of the fluid obtained from the lavage to examine for protein content.\n\nIn addition to the bronchoscopy and bronchoalveolar lavage, participants will have about 2 tablespoons of blood drawn to compare blood test results with the results of the lung washings. Patients' medical records will be reviewed to obtain information on past medical history, current medical treatment, vital signs, and results of x-ray tests.",[58,28,59],"Pneumonia","Lung Disease",[61,62,58,63,64,65,66,28,67],"Proteomics","Infection","Mass Spectrometry","BAL","Natural History","Lung","Lung Infiltrates","2026-06-18",{"date":70,"type":35},"2026-06-22",{"date":72,"type":35},"2004-02-20",{"name":74,"class":75},"National Institutes of Health Clinical Center (CC)","NIH",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":4,"leadSponsor":101,"locationsCount":43},"100188549","natural-history-study-of-biomarkers-in-pulmonary-arterial-hypertension-100188549","NCT01730092","Natural History Study of Biomarkers in Pulmonary Arterial Hypertension","A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension","* ELIGIBILITY:\n\nThe study will enroll subjects with confirmed and suspected NYHA\u002FWHO Group 1 PH (68) as well as age and sex matched control subjects. Subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study. There is no exclusion based on race or sex.\n\nINCLUSION AND EXCLUSION CRITERIA FOR PAH SUBJECTS:\n\nInclusion Criteria:\n\nThe following parameters on RHC are required to meet the hemodynamic definition of PAH (NYHA\u002FWHO Group I PH):\n\n* mean pulmonary artery pressure of \\> 25 mmHg at rest,\n* pulmonary capillary wedge pressure of \\\u003C 15 mmHg (or a left ventricular end-diastolic pressure of \\\u003C 12 mmHg), and\n* pulmonary vascular resistance of \\> 3 Wood units (240 dyn s cm-5).\n\nFor patients with suspected PAH (Group I PH) who have not undergone a RHC and\u002For additional testing to confirm the diagnosis, this testing will be completed as clinically indicated under a procedural consent. If clinically indicated (diagnostic) testing indicates that the subject with suspected PAH does not in fact meet standard criteria for PAH (Group I PH), then the subject will be removed from the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women (all women of childbearing potential will be required to have a screening urine or blood pregnancy test)\n* Age less than 18 years\n* Inability to provide informed written consent for participation in the study\n\nINCLUSION AND EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS:\n\nInclusion Criteria for Control Subjects\n\nAny healthy man or woman who is the appropriate age and sex for matching to a PAH patient\n\n* Must be eligible for MRI and Gadolinium Based MRI studies\n* Must be eligible for CT and Iodine Based Contrast CT studies\n\nExclusion Criteria for Healthy Control Subjects\n\n* Current pregnancy or breastfeeding (All women of childbearing potential will be required to have a screening urine or blood pregnancy test)\n* Electrocardiographic evidence of clinically relevant heart disease\n* Symptoms of coronary or cardiac insufficiency\n* More than one major risk factor for coronary artery disease (excluding age and sex)\n* Obesity (defined as a body mass index \\> 30 kg\u002Fm\\^2)\n* History of underlying conditions\u002Frisk factors associated with pulmonary hypertension such as collagen vascular disease, HIV infection, use of appetite suppressants, chronic liver disease or cirrhosis of the liver, chronic thromboembolic disease, congenital heart defects, hypoxemia and\u002For significant pulmonary parenchymal disease\n* Systemic hypertension that is not well controlled (i.e. blood pressure at the time of screening \\>140\u002F90 mmHg in adults \\\u003C 60 years old or \\>150\u002F90 mmHg in adults 60 years or older) on medications. Subjects taking \\> 2 anti-hypertensive medications will be excluded irrespective of their current blood pressure at time of screening\n* Anemia, thrombocytopenia or coagulopathy\n* Renal insufficiency (defined as an estimated glomerular filtration rate of \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2 of body surface area)\n* Active tobacco use (\\> 6 months) in the past ten years, any tobacco use within 3 months prior to the screening evaluation or any tobacco use prior to completion of the study\n* Inability to provide informed written consent for participation in the study\n* History of recreational drug use with the exception of marijuana (as long as marijuana use was \\> 3 months from the time of study screening).\n\n  * Volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer.\n\nExclusion Criteria for MRI in Healthy Control Subjects and Subjects with PAH\n\nThese contraindications include but are not limited to the following devices or conditions:\n\n1. Implanted cardiac pacemaker or defibrillator\n2. Cochlear Implants\n3. Ocular foreign body (e.g. metal shavings)\n4. Embedded shrapnel fragments\n5. Central nervous system aneurysm clips\n6. Implanted neural stimulator\n7. Any implanted device that is incompatible with MRI\n8. Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and severe dyspnea at rest\n9. Subjects requiring monitored sedation for MRI studies\n10. Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.)\n11. Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.\n\nExclusion Criteria for Gadolinium Based MRI Studies Only:\n\n1. History of severe allergic reaction to gadolinium contrast agents despite pre- medication with diphenhydramine and prednisone\n2. Chronic kidney disease (an estimated glomerular filtration rate of \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2 of body surface area)\n\nExclusion Criteria for Cardiac Computed Tomography in Healthy Control Subjects and Subjects with PAH:\n\n1\\) Subjects with a condition precluding entry into the scanner (e.g. morbid\n\nobesity, claustrophobia, etc.)\n\nExclusion Criteria for Iodine Based Contrast CTA Studies Only:\n\n1. Serum creatinine \\> 1.4 mg\u002FdL\n2. History of multiple myeloma\n3. Use of metformin-containing products less than 24 hours prior to contrast administration\n4. History of significant allergic reaction to CTA contrast agents despite pre-medication with diphenhydramine and prednisone",true,"100 Years",{"count":86,"type":20},270,"Background:\n\n\\- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH.\n\nObjectives:\n\n\\- To study the natural history of PAH.\n\nEligibility:\n\n* Individuals at least 18 years of age who have PAH.\n* Healthy volunteers at least 18 years of age.\n\nDesign:\n\n* Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center. After the first visit, they will return in 6 months and then yearly or every other year for as long as the study continues.\n* The first visit will take up to 3 days. It will involve the following tests:\n* Physical exam and medical history\n* Blood and urine samples\n* Heart and lung function tests and imaging studies\n* Six-minute walk test\n* Questions about exercise and physical activity\n* Healthy volunteers will have only one visit to the Clinical Center, during which they will undergo screening tests, and complete many of the same tests as patients with PAH",[28,89],"Pulmonary Hypertension",[91,92,93,94,95,65],"Vascular Inflammation","Microarray","Right Ventricular Function","Endothelial Dysfunction","Magnetic Resonance Imaging","2026-06-13",{"date":98,"type":35},"2026-06-16",{"date":100,"type":35},"2013-07-15",{"name":74,"class":75},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100551158","taiwan-severe-asthma-biologic-registry-100551158","NCT06456450","Taiwan Severe Asthma Biologic Registry","TARGET","Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures.\n* Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case.\n* Female and male aged over 18 years old.\n* Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020.\n\nExclusion Criteria:\n\n* Lack of informed consent for participation.\n* History of Biologic usage before January 1, 2020, should be ruled out.\n* The washout period should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his\u002Fher biologic initiation.\n* Comorbid pulmonary diseases (e.g.: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma.",{"count":110,"type":20},500,"This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan.\n\nThe goal of this observational study is to discover the real-world effectiveness, the impact of initiating, switching of biologics, and the possible prediction factors for selecting the best treatment option for patients.\n\nThe main question\\[s\\] it aims to answer are:\n\n1. Determine risk factors associated with poor asthma control.\n2. Support the development of effectiveness and safety of therapeutic principles\n3. To discover the real-world effectiveness of different biologics ( Clinical remission)\n4. To discover the impact of initiating biologics for severe asthma patients.\n5. To evaluate the prevalence of biologics switching and its benefits for patients.\n6. To compare the achievement rate of clinical remission among different biologics.\n\nParticipants who are treated either with omalizumab, mepolizumab, benralizumab dupilzumab or Tezepelumab after January 1, 2020 will be included in the study.",[28,113],"Asthma",[115,116,117],"Severe Asthma","Registry","Biologic","2026-05-17",{"date":120,"type":35},"2026-05-19",{"date":122,"type":35},"2023-11-11",{"date":124,"type":20},"2043-02-28",{"name":126,"class":42},"Taichung Veterans General Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":55,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":43},"100480009","quantitative-pulmonary-imaging-registry--biorepository-100480009","NCT05530408","Quantitative Pulmonary Imaging Registry & Biorepository","PIBR","Inclusion Criteria:\n\n* The participant is enrolling\u002Fhas enrolled in a research study at the University of Kansas Medical Center that involves Pulmonary MRI and\u002For Pulmonary CT.\n\nExclusion Criteria:\n\n* The participant declines to participate.",{"count":135,"type":20},100,"3 Months","The goal of this project is to establish a registry and biorepository of images and biological samples from subjects undergoing novel pulmonary imaging methods to be used for future research aimed toward identifying clinical applications of imaging methods and toward understanding the physiological significance of imaging biomarkers. This registry and biorepository will accelerate the development of these imaging techniques and may lead toward future clinical adoption of quantitative pulmonary imaging.",[28],[140,141,142],"Xenon","Xe-129","CT","2026-04-30",{"date":145,"type":35},"2026-05-06",{"date":147,"type":35},"2022-05-24",{"date":149,"type":20},"2028-05-31",{"name":151,"class":42},"University of Kansas Medical Center",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":164,"conditions":165,"keywords":170,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100414454","functional-lung-avoidance-spect-guided-radiation-therapy-of-lung-cancer-100414454","NCT04676828","Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer","Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial","ASPECT","Inclusion Criteria:\n\n* histologically verified lung cancer (small-cell and non-small cell lung cancer)\n* referred for radiotherapy with curative intent\n* radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard\n* concurrent chemotherapy is accepted\n* patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy\n* receiving (chemo)-radiotherapy to the thoracic disease with curative intent\n* adults over 18, that have given oral and written informed consent before patient registration.\n\nExclusion Criteria:\n\n* concurrent immunotherapy\n* previous radiotherapy to the thorax\n* other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol",{"count":161,"type":20},90,[163],"NA","Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)\u002FCT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.",[166,167,168,28,169],"Lung Cancer","Radiation-Induced Disorder","Radiation Pneumonitis","Lung Function Decreased",[171,172,173],"radiation-induced lung toxicity","functional avoidance methodology","radiation therapy of lung cancer","2026-02-22",{"date":176,"type":35},"2026-02-24",{"date":178,"type":35},"2021-12-01",{"date":180,"type":20},"2028-12-01",{"name":182,"class":42},"University of Aarhus",2,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":198,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100625940","phase-1-bacteriophage-for-chronic-multidrug-resistant-mycobacterium-abscessus-subsp-abscessus-pulmonary-infection-100625940","NCT07429162","Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","DP-QB-MYA-002 Phage Cocktail for Chronic Multidrug-Resistant (MDR) Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","Inclusion Criteria:\n\n* Consent to participation\n\nExclusion Criteria:\n\n* non-consent to participation",{"count":43,"type":20},[193],"PHASE1","The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.",[196,197,28],"Mycobacterium Abscessus Infection","Bacteriophage Therapy","NOT_YET_RECRUITING","2026-02-17",{"date":176,"type":35},{"date":34,"type":20},{"date":203,"type":20},"2028-07-02",{"name":205,"class":42},"Alberta Health services",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":43},"100396365","evaluation-of-the-effect-of-pulmonary-rehabilitation-on-patients-with-high-flow-oxygen-therapy-100396365","NCT04441151","Evaluation of the Effect of Pulmonary Rehabilitation on Patients With High Flow Oxygen Therapy","Inclusion Criteria:\n\n* The age is ≥ 18 years old;\n* the hemodynamics is stable;\n* 50 \\\u003C heart rate \\\u003C 120 beats \u002F min ;\n* 90 \\\u003C systolic blood pressure \\\u003C 200mmHg ;\n* 55 \\\u003C mean arterial pressure \\\u003C 120mmHg;\n* do not increase the dose of pressor drugs for at least 2 hours;\n* intracranial pressure is stable and there are no seizures within 24 hours;\n* the respiratory state is stable;\n* the patient's finger pulse oxygen saturation ≥ 88%;\n* 10 \\\u003C respiratory frequency \\\u003C 35 beats \u002F min.\n\nExclusion Criteria:\n\n* Pregnancy;\n* acute cardio-cerebrovascular events;\n* spinal or limb fractures;\n* active bleeding.",{"count":213,"type":20},70,[163],"Evaluation of the effect of pulmonary rehabilitation on patients with high flow oxygen therapy",[28],"2026-02-06",{"date":219,"type":35},"2026-02-09",{"date":221,"type":35},"2025-03-20",{"date":223,"type":20},"2026-02-01",{"name":225,"class":42},"Chinese PLA General Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":237,"conditions":238,"keywords":242,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":257},"100451089","cooperative-assessment-of-late-effects-for-scd-curative-therapies-100451089","NCT05153967","Cooperative Assessment of Late Effects for SCD Curative Therapies","U01 Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies","COALESCE","Inclusion Criteria\n\n* Confirmed laboratory diagnosis of SCD\n* Ability to give informed consent\n* Ability to provide pre- and post-curative therapy data\n* Treated with either one HSCT or with standard disease-modifying therapy\n\nExclusion Criteria\n\n•History of non-compliance","4 Years","65 Years",{"count":54,"type":20},"Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \\>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.",[239,28,240,241],"Sickle Cell Disease","Renal Disease","Heart Disease",[243,244,245,246,247],"Myeloablative Autologous Gene Editing","Myeloablative Autologous Gene Therapy","Myeloablative allo-HSCT","Nonmyeloablative allo-HSCT","Disease-Modifying Therapy","2026-01-28",{"date":250,"type":35},"2026-01-30",{"date":252,"type":35},"2022-07-12",{"date":254,"type":20},"2027-02",{"name":256,"class":42},"Vanderbilt University Medical Center",5,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":43},"100556297","advanced-imaging-holistic-omics-biobank-100556297","NCT06523270","Advanced Imaging Holistic Omics Biobank","Inclusion Criteria:\n\n* Adult subjects (\\>18 y.o.) submitted to Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI) exams acquired with 3T scanner (MR 7700, Philips) for examination required for clinical practice or for clinical trials at the IRCCS San Raffaele Hospital who signe an Informed Consent authorizing data collection.\n\nExclusion Criteria:\n\n* Absent informed consent signed",{"count":265,"type":20},50000,"Imaging methods today represent the pillar of prevention, diagnosis, patients monitoring and treatment. Improvement in technology led the development of increasingly high-performance scanners whose potential has not yet been fully explored. In particular, recently introduced photon counting CT scanner and new high filed MRI offers a lake of latent information derived from the images (e.g. spectral data from CT) of potentially great interest and potentially able to provide new insight but that are currently mostly unexplored .These features are also called \"opportunist features\" because they are in each exam and can be freely derived from images without changing the study protocol used for clinical practice examination but extracted a posteriori from the images representing a precious source of deep characterization of the patients, equally or even more than a genomic analysis, with possible high relevance in the field of screening and prevention, being able to contribute to defining signatures indicating a particular risk of remotely developing a specific pathological condition. The prospective collection of clinical and imaging data from subjects undergoing diagnostic tests with advanced technology has the potential to increase knowledge of the pathophysiological mechanisms of different pathological conditions, to explore and validate the diagnostic-predictive value of opportunistic features not currently used in practice clinical, to increase the diagnostic and prognostic accuracy of CT and MRI examinations and to provide a unique pool for scientific research. Previous relevant experience was conducted in the United Kingdom (UK biobank) where data from over 500,000 patients have been collected in the last 10 years, providing an enormous pool for spontaneous and funded scientific research. This project (UK biobank), although of enormous scientific value, is currently obsolete in terms of the imaging technology used.",[268,269,28,270],"Oncologic Disorders","Neurologic Disorder","Cardiovascular Diseases","2026-01-14",{"date":273,"type":35},"2026-01-15",{"date":275,"type":35},"2024-09-15",{"date":277,"type":20},"2034-09-15",{"name":279,"class":42},"IRCCS San Raffaele",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":43},"100375107","hyperinflation-respiratory-therapies-in-cardiac-surgery-patients-100375107","NCT04164173","Hyperinflation Respiratory Therapies in Cardiac Surgery Patients","Hyperinflation Respiratory Therapies in Cardiac Surgery Patients: A Randomized, Observer-Blinded, Prospective Clinical Trial","Inclusion Criteria:\n\n1. Age 18 years and older\n2. Admitted to Cardiovascular ICU (CVICU) after coronary artery bypass grafting (CABG), isolated valve repair\u002Freplacement, or CABG + valve repair\u002Freplacement\n3. Cardiac surgery performed via median sternotomy\n\nExclusion Criteria:\n\n1. BMI\\>40\n2. Refusal to be consented\n3. Prior or current lung transplant patients","80 Years",{"count":289,"type":20},324,[163],"The purpose of this prospective randomized clinical trial is to evaluate three different types of hyperinflation respiratory therapies, Intermittent Positive Pressure Breathing (IPPB), Intermittent positive end expiratory pressure (EzPAP), Metaneb. Investigators will examine which hyperinflation therapy provides better lung expansion and may improve lung recovery after surgery.",[28,293],"Postoperative Complications","2025-10-31",{"date":296,"type":35},"2025-11-04",{"date":298,"type":35},"2020-06-15",{"date":300,"type":20},"2028-12-31",{"name":302,"class":42},"University of Texas Southwestern Medical Center",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":287,"enrollmentInfo":310,"targetDuration":312,"studyType":55,"phases":4,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":43},"100592831","patient-experiences-and-the-role-of-team-structures-in-pulmonary-rehabilitation-in-trkiye-100592831","NCT06998550","Patient Experiences and the Role of Team Structures in Pulmonary Rehabilitation in Türkiye","Patient Experiences and the Role of Team Structures in Pulmonary Rehabilitation in Türkiye: The PRETTY Study - A National, Multicenter, Cross-Sectional Observational Study","Patient Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed with a respiratory condition (e.g., COPD, interstitial lung disease, asthma, bronchiectasis, etc.)\n* Completed a structured PR program (minimum duration and frequency as defined by national guidelines or center-specific protocols)\n* Willing and able to complete the online Patient Satisfaction Questionnaire\n* Able to provide informed consent\n\nPatient Exclusion Criteria:\n\n* Ongoing participation in a PR program (only completed cases will be included)\n* Inability to complete the questionnaire due to cognitive or language barriers without a caregiver\n\nCoordinator Inclusion Criteria:\n\n* Officially designated as the PR program coordinator or responsible team member\n* Affiliated with a healthcare institution (public, university-affiliated, or private) in Türkiye that provides PR services\n* Willing to complete the Institutional Survey Form regarding team structure, service delivery, and organizational characteristics\n* Authorized by the institution to provide structural data related to the PR unit\n\nCoordinator Exclusion Criteria:\n\n* PR services provided on an informal or ad-hoc basis without a designated team or structure\n* Institutions not offering a structured PR program",{"count":311,"type":20},384,"5 Days","The PRETTY Study aims to evaluate patient satisfaction with pulmonary rehabilitation (PR) services across Türkiye and to investigate how satisfaction levels are related to the organizational structures and team compositions of the PR programs. This national, multicenter, cross-sectional observational study will also identify structural and organizational factors that may enhance patient-centered care and promote the standardization of PR services.",[28,315],"Pulmonary Rehabilitation","2025-09-02",{"date":318,"type":35},"2025-09-09",{"date":320,"type":35},"2025-07-29",{"date":322,"type":20},"2026-06-01",{"name":324,"class":42},"Saglik Bilimleri Universitesi",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":43},"100450607","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-pulmonary-diseases-100450607","NCT05147688","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Pulmonary Diseases","Inclusion Criteria:\n\n* Diagnosis of pulmonary disease\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[193],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Pulmonary Diseases",[28,113,336],"Chronic Obstructive Pulmonary Disease",[28,113,338,336],"stem cell treatment","2025-04-15",{"date":341,"type":35},"2025-04-17",{"date":178,"type":35},{"date":344,"type":20},"2025-12",{"name":346,"class":42},"The Foundation for Orthopaedics and Regenerative Medicine",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":43},"100468312","continuous-wireless-monitoring-of-vital-signs-and-automated-alerts-in-participants-at-home-and-during-hospitalization-100468312","NCT05378139","Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","WARD Prospective Study - Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","Inclusion Criteria:\n\n* Adult participants (≥18 years)\n* Patients assessed by the clinical staff as having an acute condition with risk for clinical deterioration and being either at home (with no apparent need for hospitalization), and\u002For in hospital OR\n* Patients at either at home before, in-hospital and\u002For after hospitalization for elective major surgery, defined as surgery lasting more than one hour under general- or regional anaesthesia\n\nExclusion Criteria:\n\n* The participant expected not to cooperate with study procedures.\n* Allergy to plaster or silicone.\n* Having pacemaker or Implantable Cardioverter Defibrillator (ICD) device.\n* Inability to give informed consent.",{"count":355,"type":20},3095,"The primary aim of this study is to test and assess the implementation and effectiveness of continuous wireless vital signs monitoring with real-time alerts on:\n\nThe frequency of patients monitored with adequate data quality as adequate clinical user satisfaction in the initial versus the last part of the trial (primary outcome).",[358,28,359,360,361,362],"Surgical Complication","Hematologic Diseases","Oncology","Cardiac Disease","Infections","2025-04-08",{"date":365,"type":35},"2025-04-11",{"date":367,"type":35},"2021-02-01",{"date":369,"type":20},"2025-12-22",{"name":371,"class":42},"University Hospital Bispebjerg and Frederiksberg",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":21,"phases":382,"briefSummary":383,"conditions":384,"keywords":388,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":398,"locationsCount":183},"100421383","a-non-pharmacological-cough-control-therapy-100421383","NCT04767074","A Non-pharmacological Cough Control Therapy","A Non-pharmacological Cough Control Therapy as an Adjuvant of Pulmonary Rehabilitation in People With Interstitial Lung Diseases and Chronic Cough - A Feasibility Study","Inclusion Criteria:\n\n* Individuals will be included if having confirmed diagnosis of any ILD by a physician (as per Canadian Thoracic Society's guideline for evaluating patients with fibrotic interstitial lung disease) and a chronic cough lasting more than 8 weeks in duration\n\nExclusion Criteria:\n\n* self-reports of moderate or large sputum production\n* effective or suspected exacerbation of the respiratory condition in the past month\n* upper respiratory tract infection in the past month\n* use of angiotensin-converting enzyme inhibitor medication\n* changes in the prescribed medication in the previous month\n* evidence of traction bronchiectasis in the HRCT\n* evidence of other medical conditions that prevent performance of an exercise training program\n* unable to read or speak in English \u002F unable to provide informed consent.","85 Years",{"count":381,"type":20},24,[163],"Coughing affects almost all individuals with ILD leading to physical, psychological and social distress and prevents individuals from performing their activities of daily living, working or socialising in public places. Unfortunately, there are no licensed medications available to treat chronic cough and the few drugs that have been tried resulted in little efficacy and significant side effects. Drug-free cough control interventions have shown promise in reducing the severity and impact of coughing on patients' lives but have not been tested in individuals with ILD. This study aims to explore the feasibility and effectiveness of a non-pharmacological cough control therapy, as an adjuvant of pulmonary rehabilitation, in patients with ILD and chronic cough (\\>8 weeks in duration).",[385,386,28,387],"Cough","ILD","Pulmonary Fibrosis",[385,386,389,390,391],"Pulmonary rehabilitation","chronic cough","non-pharmacological cough therapy","2025-03-28",{"date":394,"type":35},"2025-04-03",{"date":396,"type":35},"2020-09-01",{"date":344,"type":20},{"name":399,"class":42},"West Park Healthcare Centre",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":43},"100575655","exhaled-breath-a-novel-technique-for-rapid-diagnosis-of-respiratory-diseases-and-infections-100575655","NCT06775106","Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections","EXB","Inclusion Criteria:\n\n* Non-COVID-19 adult consented patients (\\>18yo) on ventilatory support in the ICU at OHSU\n\nExclusion Criteria:\n\n* Patients with \"severe respiratory distress\" as defined by arterial pO2 of \\\u003C60 mmHg on maximal FiO2 \\& optimal ventilator settings\n* Patient with severe hemodynamic instability as defined by (a) receiving IV infusion of 2 or more pressors or inotropic medications (Levophed, vasopressin, phenylephrine, or epinephrine) \\& (b) MAP of \\\u003C60 mmHg or SB \\\u003C80 mmHg","120 Years",{"count":135,"type":20},"This study aims to use mass spectrometry techniques to analyze exhaled patient breath in non-COVID ICU-admitted patients requiring ventilation for a rapid and accurate early detection of pulmonary diseases and inflammatory markers.",[28,411],"Critical Illness",[413,414,415,416],"ventillator","critical care","pulmonary disease","inflammatory biomarkers","2025-01-09",{"date":419,"type":35},"2025-01-14",{"date":421,"type":35},"2024-11-30",{"date":423,"type":20},"2026-12-31",{"name":425,"class":42},"Oregon Health and Science University",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":183},"100555752","the-bern-rehab-registry-100555752","NCT06516172","The Bern Rehab Registry","The Bern Rehab Registry - a Prospective Cohort Study in Patients With Chronic Non-communicable Diseases Participating in a Comprehensive Rehabilitation Programme","BernRehabReg","Inclusion Criteria:\n\n* Patients aged 18 years and older with a chronic non-communicable disease\n* Signed general informed consent\n* Referral to a comprehensive disease-specific rehabilitation program\n\nExclusion Criteria:\n\n* Refuted or missing general informed consent for further use of health-related data and samples.",{"count":435,"type":20},30000,"This study examines the health outcomes of patients with long-term illnesses such as cancer, heart, lung, or musculoskeletal diseases who participate in a rehabilitation programme. The programme may involve staying in a facility (inpatient), visiting a facility (outpatient), home-based care supported by digital health tools (telerehabilitation), or a combination of facility- and home-based options.\n\nThe key health outcomes being measured include physical fitness and strength, body composition (like body fat and muscle mass), specific risk factors related to the diseases, and patients' self-reported health and experience outcomes, such as feelings of anxiety, depression, fatigue, overall quality of life, and satisfaction with the rehabilitation programme.\n\nThese measurements provide important information about the patients' lung, heart, and muscle health, as well as their mental well-being. They also help to predict the likelihood of further health complications, the chance of needing to be hospitalized again, and overall quality of life. This information is useful for improving the quality of care, tailoring future provision of rehabilitation services and long-term care for patients with chronic conditions.\n\nAdditionally, the study will provide insights into how new technologies like telerehabilitation are implemented, including how well they are adopted, followed, and accepted by patients.",[438,270,439,28],"Cancer","Musculoskeletal Diseases",[441,442,443,444,445,446],"Rehabilitation","Prevention","Physical Function","Mental Function","Participation","Disabilities","2024-08-15",{"date":449,"type":35},"2024-08-19",{"date":451,"type":35},"2020-12-01",{"date":453,"type":20},"2030-12",{"name":455,"class":42},"Insel Gruppe AG, University Hospital Bern",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":83,"sex":16,"minAge":463,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":21,"phases":466,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":479},"100513565","phase-4-chest-ct-using-low-concentration-iodine-contrast-media-100513565","NCT05967117","Chest CT Using Low-concentration Iodine Contrast Media","Chest CT Using Low-concentration Iodine Contrast Media - a Prospective Multicenter Comparative Study","Inclusion Criteria:\n\n* Patients aged 19 years or older, weighing less than 90 kg, and BMI less than 30 who underwent contrast-enhanced chest CT alone\n\nExclusion Criteria:\n\n1. Under the age of 18\n2. Cases where contrast-enhanced CT cannot be performed\n3. Heart failure\n4. Pregnancy\n5. If patients cannot voluntarily give written consent to participate in this clinical trial\n6. In the case of an anatomical deformation that may interfere with image analysis in the previous image\n7. Patients with a history of hypersensitivity to IOBRIX, components of IOBRIX, and iodine-based drugs\n8. Patients with severe thyroid disease (Iodine may accumulate in the thyroid gland and worsen symptoms.)\n9. Those who are judged unsuitable by the tester for other reasons Patients aged 19 years or older, weighing less than 90 kg, and BMI less than 30 who underwent contrast-enhanced chest CT alone","19 Years",{"count":465,"type":20},370,[467],"PHASE4","This study aims to evaluate the quality of images when low-concentration iodine contrast agents is used in chest CT with low tube voltage and if they can be used in routine imaging.\n\nThe primary endpoint of the study was the quality of the image and comparison of chest CT by using low and conventional concentration iodine contrast agents with low tube voltage and chest CT by using the conventional concentration iodine contrast agents with the conventional tube voltage; The secondary endpoint is optimizing chest CT protocol using an iodine contrast agent.",[28],"2024-07-23",{"date":472,"type":35},"2024-07-25",{"date":474,"type":35},"2023-11-24",{"date":476,"type":20},"2024-11",{"name":478,"class":42},"Jung Im Jung",6,{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":16,"minAge":488,"maxAge":379,"enrollmentInfo":489,"targetDuration":4,"studyType":21,"phases":491,"briefSummary":492,"conditions":493,"keywords":496,"overallStatus":198,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":4},"100552464","investigating-muscle-trainings-respiratory-outcomes-and-voice-enhancement-in-parkinsons-disease-100552464","NCT06473428","Investigating Muscle Training's Respiratory Outcomes and Voice Enhancement in Parkinson's Disease","The Association of Pulmonary Function, Diaphragm Thickness and Excursion, and Phonatory Measures in Parkinson's Disease","IMPROVE-PD","Inclusion Criteria:\n\n* Patients with Parkinson's disease (Hoehn \\& Yahr stage I-III),\n* Patients aged 30-85\n* Patients with stable medical condition, regular medication adherence, and ability to follow instructions.\n\nExclusion Criteria:\n\n* Patients with cognitive impairment\n* Patients with respiratory or other neurological diseases\n* Patients with smoking history\n* Patients with respiratory complications\n* Patients with recent chest\u002Fabdominal surgery\n* Patients with clinical instability\n* Patients who are unable to perform pulmonary function tests correctly","30 Years",{"count":490,"type":20},45,[163],"This study aims to investigate the effects of different types of respiratory muscle training on lung function, diaphragm movement, and voice quality in patients with Parkinson's disease (PD). PD often leads to breathing difficulties and voice abnormalities due to weakened respiratory muscles and reduced diaphragm mobility. The study will involve 45 participants with PD, randomly assigned to three groups: one group will perform inspiratory muscle training, the second group will perform both inspiratory and expiratory muscle training, and the third group will receive placebo-controlled expiratory muscle training. The hypothesis is that targeted respiratory muscle training will significantly improve pulmonary function, diaphragm excursion, and phonatory measures compared to the placebo group. The findings aim to develop effective rehabilitation strategies to enhance the quality of life and communication abilities in individuals with PD.",[494,28,495],"Parkinson Disease","Voice Disorders",[497,498,499,500],"Parkinson's disease","Pulmonary function","Respiratory muscle training","Diaphragm","2024-06-18",{"date":503,"type":35},"2024-06-25",{"date":505,"type":20},"2024-07-01",{"date":507,"type":20},"2027-06-30",{"name":509,"class":42},"National Taiwan University Hospital",{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":21,"phases":519,"briefSummary":520,"conditions":521,"keywords":537,"overallStatus":198,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":4},"100354774","phase-1-safety-and-clinical-outcomes-with-amniotic-and-umbilical-cord-tissue-therapy-for-numerous-medical-conditions-100354774","NCT03899298","Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions","Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n3. Competent to understand the study protocol and provide voluntary informed consent.\n4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back\u002FNeck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnancy, Lactating\n3. Severe Clotting disorder\n4. Myocardial Infarction less than six months ago.",{"count":518,"type":20},5000,[193],"To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.",[522,269,523,524,525,526,527,528,529,530,531,28,532,533,534,535,536],"Orthopedic Disorder","Urologic Diseases","Erectile Dysfunction","Autoimmune Diseases","Renal Failure","Renal Insufficiency","Kidney Diseases","Cardiac Event","Cardiomyopathies","CHF","COPD","Alzheimer Disease","Stroke","Neuropathy;Peripheral","Arthritis",[538,539,540,541,542,543,544,545],"stem cell therapy","umbilical stem cells","amniotic stem cells","stem cells","regenerative medicine","r3 stem cell","perinatal tissue","placenta stem cell","2019-08-20",{"date":548,"type":35},"2019-08-22",{"date":550,"type":20},"2019-09-01",{"date":552,"type":20},"2029-03-20",{"name":554,"class":555},"R3 Stem Cell","INDUSTRY",{"id":557,"slug":558,"hasResults":11,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":16,"minAge":563,"maxAge":4,"enrollmentInfo":564,"targetDuration":566,"studyType":55,"phases":4,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":198,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":4},"100357438","a-prospective-registry-for-patients-with-non-tuberculous-mycobacterial-ntm-pulmonary-disease-in-korea-100357438","NCT03934034","A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.","NTM-KOREA","Inclusion Criteria:\n\n1. Clinical diagnosis of NTM pulmonary disease.\n2. The causative agent of NTM pulmonary disease includes: M. avium complex, or M. abscessus subspecies abscessus, or M. abscessus subspecies massiliense, or M. kansasii.\n3. Patients who starts new treatment (those who have previous history of treatment are eligible)\n\nExclusion Criteria\n\n1. Patients who have been treated for more than 4 weeks.\n2. The causative agent of NTM pulmonary disease is none of M. avium complex, M. abscessus subspecies abscessus, M. abscessus subspecies massiliense, or M. kansasii.","20 Years",{"count":565,"type":20},1000,"10 Years","The incidence and prevalence of pulmonary disease due to Non-tuberculous mycobacteria (NTM) is increasing worldwide, and this trend has been confirmed in Korea. Treatment of NTM pulmonary disease is difficult and usually requires more than two years of long-term treatment, and the antibiotic regimens used in treatment vary. Therefore, it is difficult to track the natural history of patients with NTM pulmonary disease, to evaluate the treatment outcome, and to understand the effect of specific medicines on the outcome. Establishing a prospective registry of patients with NTM pulmonary disease is expected to accurately evaluate the progress, treatment modality, and treatment outcome of NTM pulmonary disease.",[28,569,570],"Pulmonary Infection","Non-Tuberculous Mycobacterial Pneumonia",[572,116,573],"NTM","Pulmonary infection","2019-04-30",{"date":576,"type":35},"2019-05-01",{"date":578,"type":20},"2019-04",{"date":580,"type":20},"2029-12",{"name":582,"class":42},"Seoul National University Hospital"]